Q-omics provides the consensus-scored GRIK4 profile across patient tissues and cancer cell-line models. GRIK4 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, GRIK4 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, GRIK4 RNA expression shows 15,866 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BRCA, KIRC, and TGCT as cancer lineages where GRIK4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GRIK4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GRIK4 survival associations across molecular data types. GRIK4 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GRIK4 RNA expression–survival associations across cancer types. High GRIK4 expression shows unfavorable associations in KIRP and KIRC, but favorable associations in BRCA, HNSC, LGG and SKCM. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for GRIK4 RNA expression.
This table summarizes GRIK4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for GRIK4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GRIK4 shows lower tumor expression in LUAD, THCA and LUSC and higher tumor expression in KIRC, LIHC and BRCA. The KIRC box plot shows higher GRIK4 RNA expression in tumor versus normal tissue (log2 FC = +0.622, t-test p < 0.001).
This table shows molecular features associated with GRIK4 in patient tissues and cancer cell lines. In patient samples, GRIK4 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, GRIK4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BREAST.
